WEBULL
WebtradeDownload

Novartis (SWX:NOVN) Has Fresh Attention, What Are Investors Weighing Now?

Simply Wall St · 2d ago

Novartis (SWX:NOVN) has drawn fresh attention after regulators in Europe issued a positive opinion for expanding Cosentyx into polymyalgia rheumatica, bringing a new potential indication for this franchise to investors’ attention.

The Cosentyx update lands at a time when Novartis has seen mixed momentum, with the share price down about 8.9% over the past month and 5.9% over 90 days, yet still showing a 7.0% year-to-date share price return and a 21.7% total shareholder return over one year. Recent news has been a blend of positive and negative trial readouts, and the latest CHMP opinion on Cosentyx appears to be the key near term catalyst that investors are weighing alongside broader performance and valuation signals at the current CHF116.14 share price.

Scan beyond Novartis and this Cosentyx decision by reviewing a hand-picked 131 healthcare AI stocks that could be next in line for clinically driven catalysts.

After a sharp pullback and with Novartis trading below both intrinsic estimates and the average analyst target, investors now have to judge whether that discount reflects opportunity or instead sensible caution around execution and pipeline risk.

Most Popular Narrative: 8% Undervalued

On the most followed narrative, Novartis screens as undervalued, with a fair value of about CHF126 per share against the recent CHF116.14 close. This puts fresh focus on how future trials and pricing pressures might shape that gap.

Strong demand for innovative therapies and expansion in emerging markets support growth, while operational efficiency boosts margins and long-term profitability. Advancements in advanced therapies and substantial shareholder returns position the company for accelerated earnings and enhanced equity performance.

See why 108 investors see Novartis as 8% undervalued.

Result: Fair Value of CHF126.13 (UNDERVALUED)

Still, the story can change quickly if key late stage trials disappoint or if pricing pressure on therapies like Cosentyx and Entresto bites harder than analysts assume.

Find out about the key risks to this Novartis narrative.

Next Steps

Mixed messages around Novartis can pull investors in opposite directions, so it helps to move fast, review the data, and weigh both sides. To see a clear summary of the key worries alongside the potential upsides, take a look at the 3 key rewards and 1 important warning sign.

Looking for more investment ideas beyond Novartis?

If you want a fuller picture of what is out there, use the Simply Wall Street Screener to compare Novartis against other opportunities and sharpen your watchlist.

  • Target potential mispricing early by scanning a curated 174 high quality undervalued stocks that may offer a margin of safety relative to current market expectations.
  • Build a steadier income stream by reviewing a focused 161 dividend fortresses that highlights companies offering higher yields with supporting fundamentals.
  • Aim for resilience first by checking a 229 resilient stocks with low risk scores. This surfaces businesses with stronger risk profiles before momentum chases them higher.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.